F. Vigil

A mouse model of repetitive blast traumatic brain injury reveals post-trauma seizures and increased neuronal excitability.

J. Cavazos, J. Lechleiter, D. Holstein, 2020, Journal of neurotrauma.

Prevention of long-term memory loss after retrieval by an endogenous CaMKII inhibitor

W. Lucchesi, K. Giese, K. Mizuno, 2017, Scientific Reports.

Prevention of brain damage after traumatic brain injury by pharmacological enhancement of KCNQ (Kv7, “M-type”) K+ currents in neurons

J. Cavazos, J. Lechleiter, D. Holstein, 2020, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Neuroprotective Roles of the Adenosine A3 Receptor Agonist AST-004 in Mouse Model of Traumatic Brain Injury.

J. Cavazos, J. Lechleiter, D. Holstein, 2021, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.

Neuroprotective Roles of the Adenosine A3 Receptor Agonist AST-004 in Mouse Model of Traumatic Brain Injury

J. Cavazos, J. Lechleiter, D. Holstein, 2021, Neurotherapeutics.

Calcium/calmodulin‐dependent kinase II and memory destabilization: a new role in memory maintenance

K. Giese, F. Vigil, 2018, Journal of neurochemistry.

CaMKII Autophosphorylation-Dependent Learning and Memory

K. Giese, F. Vigil, 2016 .

Pharmacological Manipulation of Kv7 Channels as a New Therapeutic Tool for Multiple Brain Disorders

M. Shapiro, Chase M. Carver, F. Vigil, 2020, Frontiers in Physiology.

Spatial cognitive deficits in an animal model of Wernicke–Korsakoff syndrome are related to changes in thalamic VDAC protein concentrations

L. S. Resende, E. Gonçalves, A. F. Ribeiro, 2015, Neuroscience.

Spatial memory deficits and thalamic serotonergic metabolite change in thiamine deficient rats

Â. M. Ribeiro, F. Vigil, S. R. Pereira, 2010, Behavioural Brain Research.

Acute Treatment with the M-Channel (Kv7, KCNQ) Opener Retigabine Reduces the Long-Term Effects of Repetitive Blast Traumatic Brain Injuries

H. Belchior, J. Cavazos, J. Lechleiter, 2023, Neurotherapeutics.